Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update
Beverly Moy, R. Bryan Rumble, Lisa A. Carey, for the Chemotherapy and Targeted Therapy for HER2-Negative Metastatic Breast Cancer that is Either Endocrine-Pretreated or Hormone Receptor–Negative Expert Panel
Abstract
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
Topics & Concepts
GuidelineMedicineHuman Epidermal Growth Factor Receptor 2Breast cancerOncologyDisseminationMetastatic breast cancerClinical OncologyInternal medicineCancerFamily medicineGynecologyPathologyTelecommunicationsComputer scienceCancer Treatment and PharmacologyAdvanced Breast Cancer TherapiesColorectal Cancer Treatments and Studies